A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017

Japanese Journal of Clinical Oncology

Volumn 42, Issue 10, 2012, Pages 970-973

  Shien, Tadahiko ^a   Nakamura, Kenichi ^b   Shibata, Taro ^b   Kinoshita, Takayuki ^c   Aogi, Kenjiro ^d   Fujisawa, Tomomi ^e   Masuda, Norikazu ^f   Inoue, Kenichi ^g   Fukuda, Haruhiko ^b   Iwata, Hiroji ^h  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e GUNMA PREFECTURAL CANCER CENTER   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g SAITAMA CANCER CENTER   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Breast medicine; Breast basic; Metastasis; Surgery

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GOSERELIN; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES; YOUNG ADULT;

EID: 84866756749     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys120     Document Type: Article

References (11)

1. National Cancer Institute. The treatment of primary breast cancer: management of local disease. NIH Concensus Dev Conf Summ 1979;2:1-3.
2. National Institutes of Health Consensus Development Panel. Consensus statement; treatment of early stage breast cancer. Monogr Natl Cancer Inst 1992;11:1-5.
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
4. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-49.
5. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER Data. Ann Surg Oncol 2007;14:2187-94.
6. Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, et al. Effect of primary tumor extirpation in breast cancer patients who present with Stage IV disease and an intact primary tumor. Ann Surg Oncol 2005;13:776-82.
7. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620-7.
8. Shien T, Kinoshita T, Shimizu C, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep 2009;21:827-32.
9. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233-41.
10. El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W. Morbidity and mortality following breast cancer surgery in women. Ann Surg 2007;245:665-71.
11. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;38:163-70.